Idiopathic Pulmonary Fibrosis Treatment Market Analysis Report 2023-2028

by Zayn Mathew Market Research Reports

According to the latest report by IMARC Group, titled “Idiopathic Pulmonary Fibrosis Treatment Market Size: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global idiopathic pulmonary fibrosis treatment market size reached US$ 3,577 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 5,644 Million by 2028, exhibiting a growth rate (CAGR) of 7.6% during 2023-2028.

Idiopathic pulmonary fibrosis (IPF) refers to a chronic lung disease that causes the buildup of scar tissues in the lungs. This condition hinders the oxygen-carrying functionality of the lungs, thus resulting in breathing difficulties. IPF is diagnosed through various chest imaging evaluations, including lung biopsies, antibody tests, and pulmonary function tests. It can be treated through anti-fibrotic drugs and supportive treatment options, such as oxygen therapy and palliative care.

Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially in the geriatric population, and a rise in the cigarette smoking population are majorly fueling the global IPF treatment market growth. Additionally, increasing health consciousness amongst consumers and the rising awareness regarding the effective prevention and management strategies of IPF are further supporting the market growth. Moreover, rising investments in improving the healthcare infrastructure and extensive research and development (R&D) activities for introducing novel medicines for IPF are creating a positive outlook for the market.

Request Free Sample Report:

Idiopathic Pulmonary Fibrosis Treatment Market 2023-2028 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.

The report has segmented the market on the basis on region, drug class and end user.

Breakup by Drug Class:

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others

Breakup by Region:

    • North America: United States, Canada
    • Asia Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others
    • Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others
    • Latin America: Brazil, Mexico, Other
    • Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure:

Key highlights of the report:

  • Market Performance (2017-2022)
  • Market Outlook (2023-2028)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Other Related Reports:

Veterinary Diagnostics Market

Live Cell Imaging Market

Hospital Gowns Market

Medical Ceramics Market

Microfluidics Market

Orthobiologics Market

Autoimmune Disease Diagnosis Market

Companion Diagnostics Market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Sponsor Ads

About Zayn Mathew Advanced   Market Research Reports

81 connections, 0 recommendations, 349 honor points.
Joined APSense since, February 20th, 2018, From Brooklyn, United States.

Created on Jan 21st 2022 03:15. Viewed 237 times.


No comment, be the first to comment.
Please sign in before you comment.